The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ANALYSIS-Buy yen in crisis? Not this year

Tue, 24th Jul 2018 15:08

* Yen weakest G10 currency this month despite globalturbulence

* Investors doubt BOJ can reduce stimulus aggressively

* Japanese purchases of foreign equities highest in nearly 3years

* Bond investors growing reluctant to hedge foreign holdings

* Japanese firms spend record sum on foreign acquisitions inH1

By Tom Finn and Hideyuki Sano

LONDON/TOKYO, July 24 (Reuters) - The trade is familiar toinvestors worldwide: in times of turmoil, rush for cover bybuying the Japanese yen.

This year a global trade row has erupted, Donald Trump haslamented the dollar's strength - ignoring a custom that U.S.presidents avoid openly interfering in financial markets - andthe Chinese yuan has tumbled.

And yet the yen has stayed resolutely weak, becoming theweakest of the G10 developed market currencies this month.

The yen's safe-haven status is not in doubt, underpinned byJapan's nearly two trillion yen ($18 billion) monthly tradesurplus. But without a massive world market shock to discourageJapanese investors from buying foreign assets, the yen is likelyto stay weak - above all because the Bank of Japan lags behindits central bank peers in ending monetary stimulus.

Investors doubt the BOJ can aggressively reduce the stimulusmeasures as inflation remains well below target and corporateprofits are recovering slowly.

The BOJ is debating policy changes to make its stimulus"more sustainable", sources told Reuters, but this pushed theyen up only briefly on Monday.

"The Bank of Japan is still pursuing easing which is stillprompting domestic investors to borrow yen and buy overseasassets," said Anton Eser, CIO at Legal and General InvestmentManagement which manages 983 billion pounds ($1.29 trillion) inassets.

While U.S. interest rates have risen seven times since 2016and the European Central Bank plans to wind down its bondpurchases by end-2018, the BOJ is still buying local securities,albeit at a slower pace.

Japanese investors are therefore likely to keep pouringmoney into foreign assets, despite global market wobbles.

Their net purchases of foreign equities reached 1.5 trillionyen in June, the highest in nearly three years. Even as thetrade row deepened, they bought 371 billion yen of overseasstocks during the first week of July.

HEDGE TRIMMING

However, Japanese funds are growing reluctant to hedgeexposure to billions of dollars' of U.S. assets.

"I suspect some investors are reducing currency hedge ontheir foreign bond investments," a senior trader at a majorJapanese bank in Tokyo told Reuters, requesting anonymity.

Japanese fund managers buying 10-year U.S. Treasuries on afully hedged basis now earn a slim 33 basis points in yield,compared with 50-80 bps last year. As the Federal Reserve keepsraising interest rates, even that yield advantage could vanish.

And a lack of demand for yen from investors in the currencyforwards market would feed into falling spot market demand.

"Currency hedging costs have risen rapidly. Japaneseinvestors have stopped hedging. That stops them buying the yen.The flow is for selling yen," said Adam Cole, chief currencystrategist at RBC in London.

Another source of yen selling is Japanese companies makingacquisitions overseas due to lacklustre economic growth and ashrinking population at home. Thomson Reuters data showsJapanese investors spent a record 13.0 trillion yen on foreignacquisitions in the first half of the year.

These included Takeda Pharmaceutical's $62 billionacquisition of London-listed drugmaker Shire Plc.

Initially the deal helped to push the British pound up morethan four percent against the yen in early-April, but in Maytraders started to buy dollars on news that Takeda's payment toShire shareholders would be in dollars.

TRADE WINDS

Trade conflict would seem yen-positive by raising globalmarket volatility. In fact, this is helping to push it down.

Japan is vulnerable to a trade war. Autos, for instance,comprise almost 30 percent of its exports to the United Statesand new U.S. tariffs could hurt Tokyo's vaunted trade surplus.

Also, as fund managers worldwide cut foreign investmentholdings, much of this cash is going to U.S. markets instead ofthe "safe havens". The dollar is likely to benefit from a tradewar due to the United States' lower reliance on exports.

"Rather than move into the Swiss franc or the Japanese yen,the widening interest rate differential in favour of the U.S.dollar is currently providing investors with a strongalternative," Rabobank currency strategist Jane Foley said.

Global investors now hold their biggest overweight positionin U.S. equities in 17 months, Bank of America Merrill Lynch'spoll showed last week. Other equity holdings have fallen andallocations to Japan slid for the third time in four months.

Correlation has been high this year between Japanese stocksand the yen, with both losing ground, BAML's FX strategist KamalSharma noted. That's unusual because yen weakness usually booststhe Nikkei average.

"If U.S. share markets crumbled, then we would be in adifferent situation," the Tokyo-based trader said. "But as longas Wall Street is in the risk-on mode, the dollar will besupported against the yen."($1 = 111.2400 yen)($1 = 0.7629 pounds)

(Additional reporting by Shinji Kitamura and Tommy Wilkes;Graphic by Ritvik Carvalho; Writing by Saikat Chatterjee;Editing by Sujata Rao and David Stamp)

More News
6 Sep 2019 07:54

UPDATE 1-Sumitomo Dainippon Pharma investing $3 bln in Swiss Roivant in overseas push

* Dainippon to buy 10% stake in Roivant and interests in 5 units * Schizophrenia treatment Latuda to lose US exclusivity in 2023 * Japan pharma firms grapple with declining Dainippon

Read more
14 Aug 2019 06:45

UPDATE 1-Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt

FRANKFURT, Aug 14 (Reuters) - German generic drugmaker Stada will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development we

Read more
17 Jul 2019 17:55

Takeda kicks off sale of Western European drugs - sources

By Arno Schuetze and Pamela Barbaglia FRANKFURT/LONDON, July 17 (Reuters) - Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in

Read more
16 May 2019 18:35

Japan's Takeda expects binding offers for Latam business by end of May -sources

By Tatiana Bautzer SAO PAULO, May 16 (Reuters) - Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources of a

Read more
15 May 2019 08:05

Nikkei snaps 7-day losing streak helped by China's stimulus hopes

* Gains may be short-lived - analyst * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi Estate jumps on share buyback, governance reform By Hideyuki Sano and Ayai

Read more
15 May 2019 04:04

Nikkei hobbled by trade worries, disappointing earnings

* Nikkei down slightly after 7 losing sessions * Uncertainties over U.S.-China standoff keep investors on edge * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi -

Read more
14 May 2019 07:56

UPDATE 1-Japan's Takeda forecasts 193 bln yen annual operating loss on Shire deal

* 193 bln Y op loss forecast this yr vs 227.5 bln profit view of analysts * Shire acquisition made Takeda one of the world's most indebted drugmakers (Adds details of results, May 14 -

Read more
14 May 2019 07:39

Japan's Takeda expects annual loss on Shire deal

TOKYO, May 14 (Reuters) - Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar an a

Read more
9 May 2019 00:38

UPDATE 1-Novartis buys Takeda's dry eye drug for $3.4 bln

May 8 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidra for $3.4 billion, as well as potential milestone of

Read more
1 Feb 2019 06:07

Japan's Takeda posts 28 pct rise in Q3 operating profit

TOKYO, Feb 1 (Reuters) - Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple

Read more
22 Jan 2019 02:46

Nikkei dips as global growth concerns sap risk appetite

* IMF cuts global growth forecasts * Companies with big China exposure fall * Totech soars after raising earnings forecast By Ayai Tomisawa TOKYO, Jan 22 (Reuters) - in

Read more
8 Jan 2019 13:54

MARKET ANALYSIS: Optimism About Trade Talks May Generate Continued Buying Interest

WASHINGTON (Alliance News) - The major US index futures are pointing to a higher opening on Tuesday, with stocks likely to extend the strong upward move seen over the two previous about trade the

Read more
8 Jan 2019 08:58

Asian Shares Mixed Despite US-China Trade Deal Optimism

CANBERA (Alliance News) - Asian stocks ended mixed on Tuesday despite optimism over US-China trade talks as US officials held a second day of trade talks with Chinese counterparts in second day of

Read more
8 Jan 2019 07:39

Takeda takes control of Shire

(Sharecast News) - Takeda Pharmaceutical has taken full control of Shire after the legal particulars of its cash and share offer were completed.

Read more
7 Jan 2019 04:29

Takeda unlikely to sell OTC drug business -CEO

(Adds quote, other details) TOKYO, Jan 7 (Reuters) - Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it a a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.